These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 33448029

  • 1. Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial.
    Singata-Madliki M, Carayon-Lefebvre d'Hellencourt F, Lawrie TA, Balakrishna Y, Hofmeyr GJ.
    Int J Gynaecol Obstet; 2021 Aug; 154(2):256-262. PubMed ID: 33448029
    [Abstract] [Full Text] [Related]

  • 2. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M, Lawrie TA, Balakrishna Y, d'Hellencourt FC, Hofmeyr GJ.
    Reprod Health; 2021 Sep 29; 18(1):192. PubMed ID: 34587971
    [Abstract] [Full Text] [Related]

  • 3. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ, Singata-Madliki M, Batting J, Balakrishna Y, Morroni C.
    BMC Womens Health; 2024 Mar 08; 24(1):167. PubMed ID: 38459552
    [Abstract] [Full Text] [Related]

  • 4. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Lancet; 2019 Jul 27; 394(10195):303-313. PubMed ID: 31204114
    [Abstract] [Full Text] [Related]

  • 5. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ, Singata-Madliki M, Batting J, Steyn P, Thomas KK, Issema R, Beesham I, Mbatsane E, Morrison C, Deese J, Smit J, Philip N, Palanee-Phillips T, Reddy K, Onono M, Mastro TD, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    PLoS One; 2024 Jul 27; 19(5):e0299802. PubMed ID: 38722832
    [Abstract] [Full Text] [Related]

  • 6. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS, Hofmeyr GJ, Thomas KK, Rees H, Philip N, Palanee-Phillips T, Nanda K, Nair G, Onono M, Mastro TD, Lind M, Heffron R, Edward V, Deese J, Beksinska M, Beesham I, Stringer JSA, Baeten JM, Ahmed K, ECHO Trial Team.
    AIDS Res Hum Retroviruses; 2020 Aug 27; 36(8):632-640. PubMed ID: 32394723
    [Abstract] [Full Text] [Related]

  • 7. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I, Bosman S, Beksinska M, Scoville CW, Smit J, Nanda K.
    Contraception; 2022 Apr 27; 108():37-43. PubMed ID: 34848180
    [Abstract] [Full Text] [Related]

  • 8. Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial.
    Singata-Madliki M, Hofmeyr GJ, Carayon-Lefebvre d'Hellencourt F, Lawrie TA.
    BMJ Open; 2017 Nov 12; 7(11):e019205. PubMed ID: 29133336
    [Abstract] [Full Text] [Related]

  • 9. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A.
    Rev Assoc Med Bras (1992); 2006 Nov 12; 52(1):32-6. PubMed ID: 16622536
    [Abstract] [Full Text] [Related]

  • 10. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
    Ryan R, Mussa A, Singtaa-Madliki M, Batting J, Balakrishna Y, Morroni C, Hofmeyr GJ.
    Front Glob Womens Health; 2022 Nov 12; 3():887541. PubMed ID: 35669313
    [Abstract] [Full Text] [Related]

  • 11. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J, Philip N, Lind M, Ahmed K, Batting J, Beksinska M, Edward VA, Louw CE, Onono M, Palanee-Phillips T, Smit JA, Baeten JM, Donnell D, Mastro TD, Mugo NR, Nanda K, Rees H, Morrison C.
    Sex Transm Infect; 2021 Jun 12; 97(4):249-255. PubMed ID: 33208512
    [Abstract] [Full Text] [Related]

  • 12. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR, Stalter RM, Heffron R, Rees H, Scoville CW, Morrison C, Kourtis AP, Bukusi E, Beksinka M, Philip NM, Beesham I, Deese J, Edward V, Donnell D, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Clin Infect Dis; 2022 Sep 10; 75(4):586-595. PubMed ID: 34910143
    [Abstract] [Full Text] [Related]

  • 13. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
    Deese J, Chen PL, Gao X, Heffron R, Hobbs M, Lapple D, Jaspan H, Miller A, Nair G, Onono M, Palanee-Phillips T, Reddy K, Steiner MJ.
    AIDS Behav; 2023 Mar 10; 27(3):978-983. PubMed ID: 36357806
    [Abstract] [Full Text] [Related]

  • 14. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
    Beksinska M, Issema R, Beesham I, Lalbahadur T, Thomas K, Morrison C, Hofmeyr GJ, Steyn PS, Mugo N, Palanee-Phillips T, Ahmed K, Nair G, Baeten JM, Smit J.
    EClinicalMedicine; 2021 Apr 10; 34():100800. PubMed ID: 33898953
    [Abstract] [Full Text] [Related]

  • 15. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF, Bunjun R, Dabee S, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Harryparsad R, Happel AU, Gamieldien H, Qumbelo Y, Sinkala M, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Heffron R, Jaspan HB, Passmore JAS.
    J Infect Dis; 2022 Sep 13; 226(5):907-919. PubMed ID: 35263421
    [Abstract] [Full Text] [Related]

  • 16. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE, Upadhyay UD, Sokoloff A, Harper CC, Diedrich JT, Drey EA.
    Contraception; 2015 Dec 13; 92(6):553-9. PubMed ID: 26093190
    [Abstract] [Full Text] [Related]

  • 17. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
    Bunjun R, Ramla TF, Jaumdally SZ, Noël-Romas L, Ayele H, Brown BP, Gamieldien H, Harryparsad R, Dabee S, Nair G, Onono M, Palanee-Phillips T, Scoville CW, Heller KB, Baeten JM, Bosinger SE, Burgener A, Passmore JS, Jaspan H, Heffron R.
    Clin Infect Dis; 2022 Nov 30; 75(11):2000-2011. PubMed ID: 35941737
    [Abstract] [Full Text] [Related]

  • 18. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L, Bottura BF, Bahamondes MV, Gonçalves MP, Correia VM, Espejo-Arce X, Sousa MH, Monteiro I, Fernandes A.
    Hum Reprod; 2014 Oct 10; 29(10):2163-70. PubMed ID: 25085802
    [Abstract] [Full Text] [Related]

  • 19. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W, de Nazaré Silva dos Santos P, Correia VM, Borges L, Bahamondes L.
    Eur J Contracept Reprod Health Care; 2015 Feb 10; 20(1):57-63. PubMed ID: 25160484
    [Abstract] [Full Text] [Related]

  • 20. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
    Hapgood JP.
    AIDS Res Hum Retroviruses; 2020 May 10; 36(5):357-366. PubMed ID: 31797677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.